Literature DB >> 27824912

Laser Doppler Flare Imaging and Quantitative Thermal Thresholds Testing Performance in Small and Mixed Fiber Neuropathies.

Alon Abraham1, Majed Alabdali2, Abdulla Alsulaiman2, Ari Breiner1, Carolina Barnett1, Hans D Katzberg1, Leif E Lovblom3, Bruce A Perkins3, Vera Bril1.   

Abstract

INTRODUCTION: Small fiber neuropathy might be a part of typical mixed small and large fiber neuropathy, or a distinct entity, affecting exclusively small nerve fibers.
OBJECTIVES: Explore the utility of small nerve fiber testing in patients with clinical presentation suggesting small fiber neuropathy, with and without evidence for concomitant large fiber neuropathy.
METHODS: Patients attending the neuromuscular clinic from 2012 to 2015 with a clinical presentation suggesting small nerve fiber impairment, who had Laser Doppler flare imaging (LDIFlare) and quantitative thermal testing (QTT) were evaluated for this study. Patients with clinical or electrophysiological evidence for concomitant large fiber neuropathy were not excluded.
RESULTS: The sensitivities of LDIFlare, cooling and heat threshold testing were 64%, 36%, and 0% respectively for clinically highly suggestive small fiber neuropathy, 64%, 56%, and 19% respectively for mixed fiber neuropathy, and 86%, 79%, and 29% respectively for diabetic mixed fiber neuropathy. DISCUSSION: LDIFlare and cooling thresholds testing are non-invasive small nerve fiber testing modalities, with moderate performance in patients with small and mixed fiber neuropathy, and excellent performance in diabetic mixed fiber neuropathy.

Entities:  

Mesh:

Year:  2016        PMID: 27824912      PMCID: PMC5100917          DOI: 10.1371/journal.pone.0165731

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


Introduction

Small fiber neuropathy might be a part of typical common mixed fiber neuropathy, involving large and small nerve fibers concomitantly, or a distinct entity, affecting exclusively small nerve fibers[1]. Typically, small fiber neuropathy presents with positive sensory symptoms such as burning pain and allodynia, occasionally accompanied by reduced distal pinprick and temperature perception on the neurological examination, which is otherwise normal. Diagnosis is made on the basis of the clinical features, normal nerve conduction studies, and confirmed by specialized tests of small-fiber function[2]. Due to their physiologic characteristics, small nerve fibres cannot be investigated by routine electrophysiological studies, making the diagnosis particularly difficult[1]. Skin biopsy has become the pathologic gold standard used for the diagnosis of a small fiber neuropathy, considered to be a reliable and efficient technique[3], however, it is invasive and costly. Laser Doppler flare imaging (LDIFlare), and quantitative thermal testing (QTT) are non-invasive small fiber testing modalities, measuring small nerve fiber function, enabling objective confirmation of small fiber neuropathy. Nonetheless, they may be utilized also in mixed fiber neuropathies, as in diabetic sensorimotor peripheral neuropathy[4,5]. In axon reflex-mediated neurogenic vasodilatation (LDIFlare), a heat stimulus is used, activating peripheral C-fiber branches in the surrounding skin. As a result, focal increase in blood flow occurs, measured by a scanning Doppler infrared laser beam. LDIFlare was shown to be reproducible and useful, correlating with nerve fiber density[6]. QTT of cooling and thermal thresholds is increasingly used for the evaluation of peripheral nervous system function in the clinical and research domains, mainly for confirmation of small nerve fiber neuropathy, and has been found to be reliable and reproducible[7]. Both of these methods are non-invasive, and can be performed at the bedside with immediate results at a reasonable cost. In this study, we aimed to explore the utility of these small nerve fiber testing modalities in patients with symptoms suggestive for small nerve fiber impairment, not excluding those with clinical or electrophysiological evidence for mixed fiber neuropathy, regarding sensitivity and correlations with clinical and electrophysiological characteristics.

Materials and Methods

Patients attending the neuromuscular clinic from 2012 to 2015 with suspected small fiber neuropathy, performing small nerve fiber testing using LDIFlare, QTT and corneal confocal microscopy (CCM) testing, were evaluated for this study. CCM testing findings will be reported separately. Small fiber testing was performed in 3 different groups of patients. All patients had a clinical presentation suggesting small fiber neuropathy, typically with positive sensory symptoms such as burning pain and allodynia, and normal or close to normal neurological examination, excluding decreased temperature and pinprick sensation. The first group included patients with clinically highly suggestive small fiber neuropathy, defined by sensory symptoms restricted to the lower limbs, with no associated weakness, in the presence of normal neurological examination other than decreased temperature and pinprick sensation, and normal NCS. The second group included patients with clinically suspected small fiber neuropathy, not fulfilling completely the previously described definition for highly suggestive small fiber neuropathy, but also with normal NCS. The third group included patients with mixed fiber neuropathy, with abnormal NCS, defined for the purpose of this study a sural sensory nerve action potential (SNAP) below 7 μV, which is the threshold used by our laboratory. This patient group was referred to our clinic specifically for small fiber testing, and NCS done subsequently were found to be abnormal. In this retrospective study, we extracted demographic data, clinical history, neurological and electrophysiological examinations results, as well as vibration perception thresholds (VPT) and small fiber testing results using LDIFlare and QTT testing. The Research Ethics Board of the University Health Network approved the current study protocol and waived informed consent. Nerve conduction studies (NCS) were performed using the Sierra Wave instrument (Cadwell Laboratories Inc., Kennewick, WA, USA). Age- and height-adjusted NCS reference values were used, according to the standards of the Toronto General Hospital (University Health Network) electrophysiology laboratory. Limb temperature was measured prior to nerve conduction studies, and if required, warming was performed to ensure a surface temperature of ≥32.0°C in the hands and ≥31.0°C in the feet. Peroneal and sural NCS were performed using surface stimulating and recording techniques according to the standards of the Canadian Society of Clinical Neurophysiology and the American Association of Neuromuscular and Electrodiagnostic Medicine[8]. The electromyography Instrument calculated latencies, amplitudes and conduction velocities automatically. Peroneal nerve compound motor action potential (CMAP) amplitudes and Sural SNAP amplitudes were measured from first negative peak to the next positive peak. LDIFlare technique was used to measure heat induced axon reflex-mediated neurogenic vasodilation, which might be influenced by sympathetic activity and basal levels of nitric oxide[9]. Temperature on the dorsum foot temperature was standardized to 32°C using a warm blanket for at least 20 minutes. Subsequently, a skin-heating probe (Moor Instruments Ltd, Axminster, U.K.) was used to heat the skin above the first metatarsal area on the dorsum of the foot to 44°C for 20 minutes. The LDI apparatus used a scanning Doppler infrared laser beam with a wavelength of 785 nm, sufficient to penetrate skin to register the movement of blood cells in dermal capillaries. A 36 cm2 area represented a 256x256 pixel resolution with each pixel itself representing a measurement of the velocity of tissue blood flow. The total scanning time was less than five minutes per examination. The MoorLDI software (version 3.11) was used to measure blood flow in the dermal capillaries and the LDIFlare area was calculated in centimeters squared. Abnormal LDIFlare was defined < 2 cm2 based on local laboratory normative data[4,10]. Cooling and heat detection thresholds were tested using a method of limits with the TSA-II NeuroSensory Analyzer (Medoc Advanced Medical Systems, Ramat-Yishai, Israel). A stimulator with a temperature of 32°C was applied to the dorsum of the foot and hand. The temperature was gradually decreased to the first level detected by the patient as a cooler than the preceding for cooling threshold testing, and gradually increased to the first level detected by the patient as a warmer than the preceding for heat threshold testing. An average of the five levels was taken for each of the studies on the foot and hand, and compared to age-matched normative data. A catch trial, with null stimulus, was inserted randomly during testing. VPT testing was performed with a Neurothesiometer, using the method of limits[11]. The stimulus was applied to the distal pulp of the toe on each side, and the patient was requested to indicate when vibration sensation was first perceived. Stimulus strength was gradually increased from null intensity to a value in voltage at which the subject first detected vibration. Testing was carried out with the subject’s eyes closed. Three separate tests were conducted, and a mean of the three values was calculated in volts. A ‘null stimulus’ trial was added randomly to ensure the subject’s adherence and understanding. Testing generally required less than 3 min. Normal values were considered 15 or less in the toes. Skin biopsy was performed 10 cm proximal to the lateral malleolus using a 3 mm circular punch, at a depth of 4 mm, after cleaning the skin with an alcohol swab and anaesthetizing the skin with 2% lidocaine with epinephrine.

Statistical analysis

Statistical analysis was performed using SAS version 9.2 for Windows (SAS Institute, Cary, North Carolina). Baseline participant characteristics were expressed as means ± standard deviations (SD) for continuous data, or as frequency and percentage for categorical data. Continuous data was assessed for normality (Shapiro-Wilk). For each small fibre test, results were dichotomized into normal and abnormal based on reference values, and differences in characteristics between normal and abnormal participants were assessed using the student’s t-test, the Wilcoxon rank-sum test, or the χ2-test (depending on the type and distribution of the variable). Cohen’s kappa coefficient was used to determine agreement among the dichotomized small fiber tests. Pearson correlation coefficients between LDIFlare area values and clinical and electrophysiological characteristics were calculated. The Benjamini-Hochberg procedure was used to adjust for multiple comparisons between the three different dichotomizations of normal and abnormal small fiber test results in the following categories of variables: abnormal examination findings, nerve conduction studies, and small fiber tests and VPT. Due to the exploratory nature of this study, the false discovery rate for this procedure was set at 0.10, otherwise, significance was set at α-level of 0.05.

Results

The total cohort included 123 patients (S1 Dataset) with mean age of 55 ± 16 years, 61% of them were females. Common comorbidities included hypertension (40%), diabetes mellitus (26%), thyroid disease (19%), and hyperlipidemia (18%). 88% of patients had sensory symptoms in the lower limbs, and 38% had sensory symptoms in the upper limbs. On examination, muscle weakness was detected in 11%. Sensory deficits were more common for small nerve fiber modalities, including pinprick in 61% and temperature in 69%. 84% of patients had normal ankle reflexes. Electrophysiological testing showed normal mean values of amplitudes and of conduction velocities in peroneal and sural nerves in the total cohort, but abnormal nerve conduction studies, with abnormal sural nerve response were observed in 32% (Table 1).
Table 1

Clinical and electrophysiological characteristics, and additional tests results in total cohort, and compared between patients with normal and reduced LDIFlare area values.

Total CohortNormal LDIFlareReduced LDIFlarep
Number1236257
Age (years)55 ± 1652 ± 1658 ± 14<0.05
Female61%71%52%<0.05
Diabetes Mellitus26%16%37%<0.01
Duration (years)12 ± 126 ± 412 ± 11<0.05
Hypertension40%36%43%NS
Hyperlipidemia18%16%19%NS
Thyroid disease19%21%15%NS
Sensory symptoms
Upper limbs38%53%23%<0.01
Lower limbs88%92%88%NS
Abnormal examination findings
Weakness11%5%19%<0.05
Vibration47%36%60%<0.05
Proprioception19%13%27%NS
Light touch42%37%49%NS
Pinprick61%52%74%<0.05
Temperature69%65%76%NS
Ankle reflex16%7%25%<0.01
Nerve Conduction Studies
Sural nerve Amp (μV)13 ± 1015 ± 1010 ± 9<0.01
Sural nerve CV (m/s)47 ± 649 ± 546 ± 6<0.01
Peroneal nerve Amp (mv)7 ± 48 ± 36 ± 4<0.01
Peroneal nerve CV (m/s)45 ± 547 ± 542 ± 5<0.01
Additional tests results
Cooling (elevated thresholds)38%13%65%<0.01
Heat (elevated thresholds)8%3%14%<0.05
LDI mean area (mm2)2.4 ± 1.233.11 ± 1.371.66 ± 0.21<0.01
LDI area range (mm2)1.1–82–81.1–2<0.01
VPT (V)14 ± 811 ± 817 ± 8<0.01

LDIFlare—Laser Doppler Imaging Flare; NS—Non Significant; Amp—Amplitude; CV—Conduction Velocity; VPT—Vibration Perception Thresholds.

LDIFlare—Laser Doppler Imaging Flare; NS—Non Significant; Amp—Amplitude; CV—Conduction Velocity; VPT—Vibration Perception Thresholds. LDIFlare testing was performed in 119 patients, and QTT using cooling and heat thresholds testing in 120. 48% had reduced LDIFlare, 38% had elevated cooling thresholds, whereas less than 10% had abnormal heat thresholds. Reduced LDIFlare and elevated cooling thresholds were associated with older age (58 years vs. 52 years), higher risk for diabetes (37% vs. 16%, and 37% vs. 19% respectively), with longer diabetes duration (12 years vs. 6 years and 14 years vs. 5 years respectively), and less frequent upper limb symptoms (23% vs. 53%, and 24% vs. 46%), compared to patients with normal studies. Patients with abnormal LDIFlare and QTT had more frequent weakness, sensory loss for different sensory modalities (vibration, proprioception, light touch, pinprick and temperature perception), absent ankle reflexes, reduced sensory and motor amplitudes and conduction velocities in the lower limbs, and elevated VPT. However, these findings were more obvious in patients with abnormal LDIFlare and elevated cooling thresholds, than for patients with elevated heat thresholds. Patients with abnormal LDIFlare were more likely to have elevated cooling and heat thresholds, and vice versa (Tables 1 and 2).
Table 2

Comparison of clinical and electrophysiological characteristics, and additional tests results between patients with normal and elevated cooling and heat thresholds.

Cooling ThresholdsHeat Thresholds
NormalElevatedpNormalElevatedp
Number754511010
Age (years)52 ± 1758 ± 14<0.0555 ± 1655 ± 11NS
Female61%63%NS64%33%NS
Diabetes Mellitus19%37%<0.0522%67%<0.01
Duration (years)5 ± 414 ± 11<0.019 ± 1015 ± 4NS
Hypertension36%45%NS39%44%NS
Hyperlipidemia9%32%<0.0116%33%NS
Thyroid disease21%17%NS20%11%NS
Sensory symptoms
Upper limbs46%24%<0.0537%44%NS
Lower limbs89%87%NS88%100%NS
Abnormal examination findings
Weakness6%21%<0.0511%20%NS
Vibration29%74%<0.0142%89%<0.05
Proprioception12%34%<0.0116%44%<0.05
Light touch29%63%<0.0140%67%NS
Pinprick49%82%<0.0160%80%NS
Temperature59%86%<0.0168%90%NS
Ankle reflex4%33%<0.0113%40%<0.05
Nerve Conduction Studies
Sural nerve Amp (μV)15 ± 118 ± 6<0.0113 ± 105 ± 6<0.01
Sural nerve CV (m/s)48 ± 646 ± 6NS48 ± 644 ± 10NS
Peroneal nerve Amp (mv)8 ± 36 ± 4<0.057 ± 35 ± 4<0.05
Peroneal nerve CV (m/s)46 ± 542 ± 5<0.0145 ± 542 ± 7NS
Additional tests results
Cooling (elevated thresholds)33%90%<0.01
Heat (elevated thresholds)1.3%20%<0.01
LDIFlare (reduced area)27%82%<0.0145%80%<0.05
VPT (V)12 ± 618 ± 9<0.0113 ± 720 ± 12<0.01

LDIFlare—Laser Doppler Imaging Flare; NS—Non Significant; Amp—Amplitude; CV—Conduction Velocity; VPT—Vibration Perception Thresholds.

LDIFlare—Laser Doppler Imaging Flare; NS—Non Significant; Amp—Amplitude; CV—Conduction Velocity; VPT—Vibration Perception Thresholds. Sensitivities for patients with clinically highly suggestive small fiber neuropathy for LDIFlare, cooling and heat thresholds testing, were 64%, 36% and 0% respectively (Table 3).
Table 3

The clinical and electrophysiological characteristics, and sensitivities of LDIFlare, cooling and heat thresholds for diagnosing small and mixed fiber neuropathy in different neuropathy groups.

Small Fiber*Mixed**DMMixed + DM
Number11363014
Age (years)44 ± 1860 ± 1655 ± 1455 ± 16
Female67%47%43%46%
Diabetes Mellitus11%37%100%100%
Duration (years)411 ± 1112 ± 1211 ± 11
IGT0%9%--
Hypertension0%59%56%75%
Hyperlipidemia22%24%31%45%
Thyroid disease11%24%23%27%
Sensory symptoms
Upper limbs0%19%26%17%
Lower limbs100%94%93%92%
Abnormal examination findings
Weakness0%9%17%15%
Vibration0%79%62%79%
Proprioception0%37%23%45%
Light touch0%64%74%69%
Pinprick25%77%86%100%
Temperature44%82%93%93%
Ankle reflex0%32%34%62%
Nerve Conduction Studies
Sural Amp (μV)16 ± 54 ± 211 ± 94 ± 3
Sural CV (m/s)49 ± 445 ± 646 ± 646 ± 6
Peroneal Amp (mv)8 ± 25 ± 37 ± 46 ± 4
Peroneal CV (m/s)44 ± 542 ± 542 ± 540 ± 6
Small fiber tests sensitivities
LDIFlare(7/11) 64%(23/36) 64%(20/29) 69%(12/14) 86%
Cooling(4/11) 36%(20/36) 56%16/29 (55%)(11/14) 79%
Heat(0/11) 0%(7/36) 19%6/29 (21%)(4/14) 29%
Combined(7/11) 64%(26/36) 72%(22/29) 76%(14/14) 100%

* Small Fiber—Clinically highly suggestive small fiber neuropathy, in the presence of normal NCS;

** Mixed fiber—Clinical presentation suggesting small fiber impairment, in the presence of abnormal NCS;

LDIFlare—Laser Doppler Imaging Flare; IGT—Impaired gloucose tolerance; Amp—Amplitude; CV—Conduction velocity.

* Small Fiber—Clinically highly suggestive small fiber neuropathy, in the presence of normal NCS; ** Mixed fiber—Clinical presentation suggesting small fiber impairment, in the presence of abnormal NCS; LDIFlare—Laser Doppler Imaging Flare; IGT—Impaired gloucose tolerance; Amp—Amplitude; CV—Conduction velocity. Intraepidermal nerve fiber density (IENFD) testing showed reduced nerve fiber density in 3 out of 3 patients, who also had reduced LDIFlare. The sensitivities for the detection of mixed fiber neuropathy with low sural SNAP amplitude, for LDIFlare, cooling and heat thresholds testing were 64%, 56%, and 19% respectively. In patients with diabetes sensitivities were 69%, 55%, and 21% respectively. In patients with the combination of diabetes and low sural SNAP amplitude, higher sensitivities were found, of 86%, 79%, and 29% respectively, with 100% sensitivity for the combination of these tests. Agreement between the different small fiber testing modalities was good (k = 0.52, p<0.0001) between LDIFlare and cooling thresholds testing, but marginal (k = 0.11, p = 0.02) between LDIFlare and heat thresholds testing, as well as between cooling and heat thresholds testing (k = 0.22, p = 0.0002). There was statistically significant correlation between LDIFlare area values and sensory and motor conduction velocities, and VPT at the toes (Table 4).
Table 4

Pearson correlation coefficients between LDIFlare area values and clinical and electrophysiological characteristics.

Comparison measurePearson rp Value
Age (years)-0.130.20
Diabetes duration (years)0.250.23
Nerve Conduction Studies
Sural nerve Amp (μV)0.060.56
Sural nerve CV (m/s)0.270.0045
Peroneal nerve Amp (mv)0.130.20
Peroneal nerve CV (m/s)0.350.0002
Additional tests results
VPT finger (V)-0.170.10
VPT toe (V)-0.330.0011

LDIFlare—Laser Doppler Imaging Flare; Amp—Amplitude; CV—Conduction Velocity; VPT—Vibration Perception Thresholds.

LDIFlare—Laser Doppler Imaging Flare; Amp—Amplitude; CV—Conduction Velocity; VPT—Vibration Perception Thresholds.

Discussion

Our study results show that abnormal LDIFlare and QTT testing can provide objective confirmation for the presence of small fiber neuropathy, with a moderate combined sensitivity of 64%. We found clear superiority for LDIFlare testing, showing similar sensitivity of 64%, whereas QTT had much lower sensitivities (36% for cooling and 0% for heat threshold testing), not adding to the overall sensitivity (Table 3). Slightly higher combined sensitivity of 72% was demonstrated in patients with mixed fiber neuropathy, with clinical presentation suggesting small fiber neuropathy in the presence of abnormal NCS. Interestingly, sensitivity was high in the subgroup of diabetic patients with mixed fiber neuropathy, reaching 86% for LDIFlare, 79% for cooling and 29% for heat threshold testing. Combined together, they were found to be 100% sensitive for this patient subgroup. The high yield of these testing in diabetic patients with mixed fiber neuropathy might be explained by frequent small nerve fiber impairment in this particular patient subgroup, which fits the common clinical impression. The association of abnormal LDIFlare and QTT testing with mixed fiber neuropathy, as reflected by the clinical and electrophysiological examinations, is in agreement with previous studies[4,5,12-14]. Patients with abnormal small fiber testing in our cohort, had more frequent limb muscle weakness, reduced vibration and proprioception perception, and absent ankle reflexes on the neurological examination, indicating concomitant large fiber impairment. This was confirmed by NCS, showing lower sensory and motor nerve amplitudes and conduction velocities (Tables 1 and 2), and significant linear correlation between LDIFlare area values and sensory and motor conduction velocities, and VPT (Table 4). The higher frequency of large fiber impairment in patients with abnormal small fiber testing, might suggest in turn a correlation between the degree of large fiber impairment and the presence of small fiber impairment. Similarly, in a previous study of 74 consecutive patients with small fiber neuropathy, patients with reduced IENFD had relatively lower sural sensory amplitudes. Although values still fell within the normal range, concomitant early large fiber impairment could not be excluded. However, in this study similar correlations between abnormal small fiber testing and sensory deficits for different modalities were not found.[10] Nonetheless, reduced pinprick sensation has been reported in patients with reduced IENFD[15]. These findings might suggest that there is a spectrum of small and large fiber neuropathies, with mixed nerve fiber neuropathy being the rule. Patients with abnormal LDIFlare and QTT testing were older, and had a twofold risk for diabetes. These findings are not surprising, considering the known decrease in small fiber density with age,[16] and the fact that diabetes is the most common cause for small and mixed fiber neuropathy. In contrast, patients with normal LDIFlare and QTT testing, had a twofold higher frequency of upper limb sensory symptoms, which although known to exist in certain forms of small fiber neuropathy[2] and other common neuromuscular disorders (such as carpel tunnel syndrome, cervical radiculopathies, etc.), is less typical for common peripheral neuropathy. As expected, patients with abnormal LDIFlare and QTT testing had a higher frequency of abnormal pinprick and temperature sensation, which is typical for small fiber neuropathy. Among small fiber testing performed, heat threshold testing was found to be relatively inferior to cold threshold testing and LDIFlare. Elevated heat thresholds were found in less than 10% of patients, whereas LDIFlare and cold threshold testing showed abnormalities in more than 40% on average. Moreover, abnormal heat threshold testing correlated less well with clinical and electrophysiological evidence for large fiber impairment, compared with LDIFlare and cold threshold testing (Tables 1 and 2). Although abnormal LDIFlare results were correlated with abnormal QTT and vice versa, good agreement was shown for LDIFlare and cooling thresholds testing, while only marginal agreement with heat threshold testing. This might suggest that heat threshold testing is a less sensitive indicator for peripheral neuropathy, compared to its counterparts. The relative superiority of LDIFlare compared to QTT testing, and better performance of cold threshold compared to heat threshold testing, has been described previously[1]. Our study has a few limitations. Our retrospective cohort explored the performance of small fiber testing, which included LDIFlare and QTT testing. Although LDIFlare and cooling threshold testing showed satisfactory performance, the sensitivity of heat threshold testing was found to be lower than expected compared with previous literature. We have not used additional non-invasive small nerve fiber testing modalities such as the Quantitative Sudomotor Axon Reflex Test (QSART). In addition, we did not perform IENFD testing, which is currently considered to be the gold standard for small fiber neuropathy detection, in most patients. Other non-invasive small nerve fiber testing modalities, especially while combined[17], and IENFD testing[1,18], might have slightly higher sensitivities for small fiber neuropathy detection. In addition, although the total cohort number was reasonable, the number of patients with exclusive small fiber neuropathy, and patients with diabetic mixed fiber neuropathy, was relatively low. Finally, small fiber testing sensitivities might have been skewed in a positive direction in patients with mixed fiber neuropathy, as their clinical presentation suggested small fiber impairment, leading to small fiber testing. In conclusion, LDIFlare and cooling threshold testing are non-invasive small nerve fiber testing modalities, which can be performed at the bedside with immediate results. Their sensitivities are moderate for small and mixed fiber neuropathy detection, and high for diabetic mixed fiber neuropathy. LDIFlare seems to be superior to QTT, and heat threshold testing seems to be the least efficient test. Additional studies, confirming these findings and comparing these tests with additional non-invasive small fiber and IENFD testing, are warranted. (XLSX) Click here for additional data file.
  18 in total

1.  Minimum standards for electromyography in Canada: a statement of the Canadian Society of Clinical Neurophysiologists.

Authors:  C F Bolton; T J Benstead; F Grand'Maison; G S Tardif; L E Weston
Journal:  Can J Neurol Sci       Date:  2000-11       Impact factor: 2.104

2.  European Federation of Neurological Societies/Peripheral Nerve Society Guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society.

Authors:  G Lauria; S T Hsieh; O Johansson; W R Kennedy; J M Leger; S I Mellgren; M Nolano; I S J Merkies; M Polydefkis; A G Smith; C Sommer; J Valls-Solé
Journal:  Eur J Neurol       Date:  2010-07       Impact factor: 6.089

3.  Concordance between epidermal nerve fiber density and sensory examination in patients with symptoms of idiopathic small fiber neuropathy.

Authors:  David Walk; Gwen Wendelschafer-Crabb; Cynthia Davey; William R Kennedy
Journal:  J Neurol Sci       Date:  2007-03-02       Impact factor: 3.181

4.  Does the prevailing hypothesis that small-fiber dysfunction precedes large-fiber dysfunction apply to type 1 diabetic patients?

Authors:  Ari Breiner; Leif Erik Lovblom; Bruce A Perkins; Vera Bril
Journal:  Diabetes Care       Date:  2014-02-26       Impact factor: 19.112

5.  C-fiber function assessed by the laser doppler imager flare technique and acetylcholine iontophoresis.

Authors:  Alistair Q Green; Singhan T Krishnan; Gerry Rayman
Journal:  Muscle Nerve       Date:  2009-12       Impact factor: 3.217

Review 6.  Small-fiber neuropathy.

Authors:  David Lacomis
Journal:  Muscle Nerve       Date:  2002-08       Impact factor: 3.217

7.  Axon reflex-related hyperemia induced by short local heating is reproducible.

Authors:  Chung-Shin Huang; Shwu-Fen Wang; Yuan-Feen Tsai
Journal:  Microvasc Res       Date:  2012-07-14       Impact factor: 3.514

8.  Evaluation of proxy tests for SFSN: evidence for mixed small and large fiber dysfunction.

Authors:  Hamid Ebadi; Bruce A Perkins; Hans D Katzberg; Leif E Lovblom; Vera Bril
Journal:  PLoS One       Date:  2012-08-03       Impact factor: 3.240

9.  The diagnostic criteria for small fibre neuropathy: from symptoms to neuropathology.

Authors:  Grazia Devigili; Valeria Tugnoli; Paola Penza; Francesca Camozzi; Raffaella Lombardi; Giorgia Melli; Laura Broglio; Enrico Granieri; Giuseppe Lauria
Journal:  Brain       Date:  2008-06-04       Impact factor: 13.501

10.  The rate of decline in small fibre function assessed using axon reflex-mediated neurogenic vasodilatation and the importance of age related centile values to improve the detection of clinical neuropathy.

Authors:  Prashanth R J Vas; Gerry Rayman
Journal:  PLoS One       Date:  2013-07-25       Impact factor: 3.240

View more
  11 in total

Review 1.  Diabetes Distal Peripheral Neuropathy: Subtypes and Diagnostic and Screening Technologies.

Authors:  Kelley Newlin Lew; Tracey Arnold; Catherine Cantelmo; Francky Jacque; Hugo Posada-Quintero; Pooja Luthra; Ki H Chon
Journal:  J Diabetes Sci Technol       Date:  2022-01-07

2.  High-resolution axon reflex sweat testing for diagnosis of neuropathy.

Authors:  Adam Loavenbruck; Nathan Sit; Vincenzo Provitera; William Kennedy
Journal:  Clin Auton Res       Date:  2018-07-21       Impact factor: 4.435

3.  The sensitivity and specificity of the neurological examination in polyneuropathy patients with clinical and electrophysiological correlations.

Authors:  Alon Abraham; Majed Alabdali; Abdulla Alsulaiman; Hana Albulaihe; Ari Breiner; Hans D Katzberg; Danah Aljaafari; Leif E Lovblom; Vera Bril
Journal:  PLoS One       Date:  2017-03-01       Impact factor: 3.240

4.  Axon reflex-mediated vasodilation is reduced in proportion to disease severity in TTR-FAP.

Authors:  Irène Calero-Romero; Marc R Suter; Bernard Waeber; Francois Feihl; Thierry Kuntzer
Journal:  Neurol Genet       Date:  2018-08-02

5.  Therapeutic potential of pravastatin for random skin flaps necrosis: involvement of promoting angiogenesis and inhibiting apoptosis and oxidative stress.

Authors:  Jinti Lin; Chang Jia; Yongli Wang; Shanghong Jiang; Zhenyu Jia; Nan Chen; Shimin Sheng; Shihen Li; Liangfu Jiang; Huazi Xu; Kailiang Zhou; Yijie Chen
Journal:  Drug Des Devel Ther       Date:  2019-05-01       Impact factor: 4.162

6.  Betulinic Acid Enhances the Viability of Random-Pattern Skin Flaps by Activating Autophagy.

Authors:  Jiafeng Li; Guodong Bao; Eman ALyafeai; Jian Ding; Shihen Li; Shimin Sheng; Zitong Shen; Zhenyu Jia; Chen Lin; Chenxi Zhang; Zhiling Lou; Huazi Xu; Weiyang Gao; Kailiang Zhou
Journal:  Front Pharmacol       Date:  2019-09-13       Impact factor: 5.810

Review 7.  Cardiac Autonomic Neuropathy in Obesity, the Metabolic Syndrome and Prediabetes: A Narrative Review.

Authors:  Scott M Williams; Aikaterini Eleftheriadou; Uazman Alam; Daniel J Cuthbertson; John P H Wilding
Journal:  Diabetes Ther       Date:  2019-09-24       Impact factor: 2.945

8.  FGF21 augments autophagy in random-pattern skin flaps via AMPK signaling pathways and improves tissue survival.

Authors:  Kailiang Zhou; Huanwen Chen; Jinti Lin; Hui Xu; Hongqiang Wu; Guodong Bao; Jiafeng Li; Xiangyang Deng; Xiaolong Shui; Weiyang Gao; Jian Ding; Jian Xiao; Huazi Xu
Journal:  Cell Death Dis       Date:  2019-11-18       Impact factor: 8.469

9.  Gastrodin Promotes the Survival of Random-Pattern Skin Flaps via Autophagy Flux Stimulation.

Authors:  Hongyu Chen; Baoxia Chen; Baolong Li; Xiaobin Luo; Hongqiang Wu; Chenxi Zhang; Junling Liu; Jingtao Jiang; Bin Zhao
Journal:  Oxid Med Cell Longev       Date:  2021-01-09       Impact factor: 6.543

Review 10.  Laser Doppler Assessment of Vasomotor Axon Reflex Responsiveness to Evaluate Neurovascular Function.

Authors:  Marie Luise Kubasch; Anne Sophie Kubasch; Juliana Torres Pacheco; Sylvia J Buchmann; Ben Min-Woo Illigens; Kristian Barlinn; Timo Siepmann
Journal:  Front Neurol       Date:  2017-08-14       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.